Comparing the current results to its competitors, Lakeshore Biopharma Co Ltd reported Revenue decrease in the 4 quarter 2024 year on year by -19.18 %, despite the revenue increase by the most of its competitors of 329.53 %, recorded in the same quarter.
Lakeshore Biopharma Co Ltd's Comment on Competition and Industry Peers
The company faces competition from biopharmaceutical and specialty pharmaceutical companies, generic drug companies, biologics drug companies, academic institutions, government agencies, and research institutions. For the YSJA TM rabies vaccine marketed in China, primary competition originates from China-based pharmaceutical companies. Other product candidates face competition from a broad range of global and local pharmaceutical companies. Many competitors possess significantly greater financial, technical, and human resources, and industry mergers and acquisitions may consolidate resources among fewer competitors. The company's commercial opportunities may be reduced or eliminated if competitors develop or market more effective, safer, or less costly products or obtain regulatory approval more rapidly.
Publicly Traded Peers of Lakeshore Biopharma Co Ltd
Alzamend Neuro Inc Share Performance
-12.83%
This Year
Alzamend Neuro Inc
Profile
Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer's disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.
Compass Pathways Plc is a mental healthcare company focused on developing innovative therapies for treatment-resistant depression. They are pioneering the use of psychedelic-assisted therapy to address this significant unmet medical need. With a business model centered around clinical research and drug development, their goal is to bring their therapies to market and improve the lives of patients suffering from depression.
Bright Minds Biosciences Inc is a biotechnology company that focuses on developing novel therapies for neuropsychiatric diseases. Their business model involves conducting research and development to discover and develop proprietary drug candidates, with the aim of partnering or licensing them to pharmaceutical companies for further clinical development and commercialization.
Sources:
Lakeshore Biopharma Co Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lakeshore Biopharma Co Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
